Amendment vs bill Amendment H1 vs SB 639

Struck = removed from the bill · added = the amendment's new text.

Previous
Latest
Stricken language would be deleted from and underlined language would be added to present law.
Hall of the House of Representatives 93rd General Assembly - Regular Session, 2021 Amendment Form ______________________________________________________________________ Subtitle of Senate Bill No.
State of Arkansas As Engrossed:
639 TO AUTHORIZE OFF-LABEL USE OF DRUG TREATMENTS TO TREAT PATIENTS DIAGNOSED WITH PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTION.
S4/15/21 H4/21/21 93rd General Assembly A Bill Regular Session, 2021 SENATE BILL 639 5 By:
______________________________________________________________________ Amendment No.
Senator K.
1 to Senate Bill 639 Amend Senate Bill No.
Hammer By:
639 as engrossed S4/15/21 (version:
Representative Cloud 8 For An Act To Be Entitled AN ACT TO AUTHORIZE OFF-LABEL USE OF DRUG TREATMENTS TO TREAT PATIENTS DIAGNOSED WITH PEDIATRIC ACUTE- ONSET NEUROPSYCHIATRIC SYNDROME AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTION;
04/15/2021 01:46:18 PM):
AND FOR OTHER PURPOSES.
Page 4, delete line 1, and substitute the following:
Subtitle TO AUTHORIZE OFF-LABEL USE OF DRUG TREATMENTS TO TREAT PATIENTS DIAGNOSED WITH PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTION.
"requirements and any standard prior authorization review of a healthcare insurer or a health benefit plan;
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:
and" *.ANS461* By:
SECTION 1.
Representative Cloud_______________________________________________________________________________ ANS/ANS - 04-20-2021 08:33:12 _________________________ ANS461 Chief Clerk
Arkansas Code Title 23, Chapter 79, Subchapter 19, is amended to add an additional section to read as follows:
23-79-1903.
Off-label use of drug treatment to treat pediatric acute- onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection — Legislative findings — Definitions.
(a) The General Assembly finds that:
(1) Pediatric acute-onset neuropsychiatric syndrome, also known as "PANS", is a clinically defined disorder characterized by the sudden onset of obsessive-compulsive symptoms or eating restrictions, accompanied by two *ANS396* 04-21-2021 10:48:25 ANS396 As Engrossed:
S4/15/21 H4/21/21 SB639 (2) or more symptoms of acute behavioral deterioration or motor and sensory changes, or both;
(2) Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection, also known as "PANDAS", is a term used to describe a subset of symptoms affecting children and adolescents within the broader PANS classification;
(3) Other states may require coverage for off-label use of drug treatments to treat pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection;
and (4) Arkansas does not require coverage for off-label use of drug treatments to treat patients who are diagnosed with pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.
(b) As used in this section:
(1)(A) “Health benefit plan” means an individual, blanket, or any group plan, policy, or contract for healthcare services issued, renewed, or extended in this state by a healthcare insurer, health maintenance organization, hospital medical service corporation, or self-insured governmental or church plan in this state.
(B) “Health benefit plan” includes:
(i) A plan offered by a risk-based provider organization as established under the Medicaid Provider-Led Organized Care Act, § 20-77-2701 et seq.;
(ii) Indemnity and managed care plans;
and (iii) Plans providing health benefits to state and public school employees under § 21-5-401 et seq.
(C) “Health benefit plan” does not include:
(i) A plan that provides only dental benefits or eye and vision care benefits;
(ii) A disability income plan;
(iii) A credit insurance plan;
(iv) Insurance coverage issued as a supplement to liability insurance;
(v) Medical payments under an automobile or homeowners' insurance plan;
04-21-2021 10:48:25 ANS396 As Engrossed:
S4/15/21 H4/21/21 SB639 (vi) A health benefit plan provided under Arkansas Constitution, Article 5, § 32, the Workers' Compensation Law, § 11-9-101 et seq., and the Public Employee Workers' Compensation Act, § 21-5-601 et seq.;
(vii) A plan that provides only indemnity for hospital confinement;
(viii) An accident-only plan;
or (ix) A specified disease plan;
and (2)(A) "Healthcare insurer" means any insurance company, hospital and medical service corporation, or health maintenance organization that issues or delivers health benefit plans in this state and is subject to any of the following laws:
(i) The insurance laws of this state;
(ii) Section 23-75-101 et seq., pertaining to hospital and medical service corporations;
(iii) Section 23-76-101 et seq., pertaining to health maintenance organizations;
Show all 50 changed rows (10 more)
Previous
Latest
or (iv) A risk-based provider organization established under the Medicaid Provider-Led Organized Care Act, § 20-77-2701 et seq.
(B) "Healthcare insurer" does not include an entity that provides only dental benefits or eye and vision care benefits.
(c) A health benefit plan that is offered, issued, or renewed in this state, including a plan offered by a risk-based provider organization established under the Medicaid Provider-Led Organized Care Act, § 20-77-2701 et seq., shall provide coverage for off-label use of intravenous immunoglobulin, also known as "IVIG", to treat individuals diagnosed with pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection, or both, on or after January 1, 2022, under a patient-specific treatment plan established by the Childhood Post-infectious Autoimmune Encephalopathy Clinic established by the University of Arkansas for Medical Sciences in collaboration with Arkansas Children's Hospital.
(d) The coverage for off-label use of drug treatment to treat pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection under this section:
(1) May be subject to policy deductions or copayment 04-21-2021 10:48:25 ANS396 As Engrossed:
S4/15/21 H4/21/21 SB639 requirements and any standard prior authorization review of a healthcare insurer or a health benefit plan;
and (2) Does not diminish or limit benefits otherwise allowable under a health benefit plan.
(e) The Insurance Commissioner shall develop and promulgate rules for the implementation and administration of this section.
8 /s/K.
Hammer 4 04-21-2021 10:48:25 ANS396